Dipeptidyl peptidase 4 (DPP-4) inhibitors do not appear to increase the risk of developing inflammatory bowel disease (IBD), according to a meta-analysis published in the Annals of Pharmacotherapy.

DPP-4 inhibitors use was used in 54% of treatment visits by the last quarter of 2014; ACEIs and ARBs were prescribed in the majority of treatment visits with peaks above 90%.